Amgen-partnered researchers treat diabetes in mice by silencing IL-2's inflammatory power

The cell-signaling molecule interleukin-2 (IL-2) plays two very distinct roles in the immune system. It’s capable of either activating or containing inflammatory responses, depending on which cells predominantly respond to its signaling.

Now, scientists at Benaroya Research Institute, in collaboration with researchers at Amgen, have engineered a manmade IL-2 protein that has its pro-inflammatory feature muted.